Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Impax Laboratories, LLCex99-1.htm
EX-99.2 - EXHIBIT 99.2 - Impax Laboratories, LLCex99-2.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): May 10, 2016

 

 

Impax Laboratories, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-34263

 

65-0403311

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

30831 Huntwood Avenue, Hayward, CA

 

94544

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

(510) 240-6000

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 
 

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On May 10, 2016, Impax Laboratories, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2016. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

 

Item 7.01

Regulation FD Disclosure.

 

On May 10, 2016, the Company posted certain presentation materials on its website located at www.impaxlabs.com. The presentation materials are attached hereto as Exhibit 99.2 and incorporated herein by reference.

 

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

 

Item 9.01

Financial Statements and Exhibits.

 

 

(d)

Exhibits.

     
   

The following exhibits are furnished herewith.

 

Exhibit No.

 

Description

99.1

 

Press release issued May 10, 2016.

99.2

 

Presentation dated May 10, 2016.

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: May 10, 2016

IMPAX LABORATORIES, INC.  

 

 

 

 

 

 

 

 

 

 

 

 

By: 

/s/ Bryan M. Reasons

 

 

 

 

 

 

 

 

Name:

Bryan M. Reasons 

 

 

 

Title:

Senior Vice President, Finance and Chief Financial Officer  

 

 

 
 

 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press release issued May 10, 2016.

99.2

 

Presentation dated May 10, 2016.